Targets › VSIR
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2029.
Immunoregulatory receptor which inhibits the T-cell response. May promote differentiation of embryonic stem cells, by inhibiting BMP4 signaling (By similarity). (UniProt, Q9H7M9)
Open in Phaseline: the race on VSIR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| PharmAbcine | PMC-309 monoclonal antibody against VISTA ligand | VSIR | Phase 1 | Advanced or Metastatic Solid Tumors | Oct 2029 |
Advanced or Metastatic Solid Tumors (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.